Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Protein Structure Readouts of Cancer Drivers for Precision Medicine

Version 1 : Received: 13 August 2021 / Approved: 16 August 2021 / Online: 16 August 2021 (11:15:11 CEST)

How to cite: Dhanjal, J.K.; Kalra, R.S. Protein Structure Readouts of Cancer Drivers for Precision Medicine. Preprints 2021, 2021080321 (doi: 10.20944/preprints202108.0321.v1). Dhanjal, J.K.; Kalra, R.S. Protein Structure Readouts of Cancer Drivers for Precision Medicine. Preprints 2021, 2021080321 (doi: 10.20944/preprints202108.0321.v1).

Abstract

Cancer is fundamentally a disease of perturbed genes. Although many mutations can be marked in the genome of a cancer or transformed cell, the initiation and progression were shown to be driven by only a few mutational events viz. driver mutations that progressively govern and execute the functional impacts. The driver mutations are thus believed to dictate and dysregulate the subsequent cellular proliferative function/decisions thereby producing a cancerous state. Therefore, identifying the driver events from the genomic alterations in a patient’s cancer cell gained large attention recently for designing better targeting therapies towards paving way for the precision cancer medicine. With rolling advancements in high-throughput omics technologies, analysis of genetic variations and gene expression profiles for cancer patients has become a routine clinical practice. However, it is anticipated that protein structural alterations resulting from such driver mutations can provide more direct and clinically relevant evidence of disease states than genetic signatures alone. This review comprehensively discusses various aspects and approaches that have been developed for the prediction of cancer drivers using genetic signatures and protein structures, and their potential application in developing precision cancer therapies.Keywords:

Keywords

cancer; mutations; cancer drivers; precision medicine; protein structure; personalized medicine; cancer therapies; genetic signatures

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.